LP
BMRN icon

LMR Partners’s BioMarin Pharmaceuticals BMRN Stock Holding History

LMR Partners’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-9,800
Closed -$693K – 1392
2025
Q1 		$693K Hold
9,800
– – 0.01% 857
2024
Q4 		$644K Sell
9,800
-100,000
-91% -$6.7M 0.01% 794
2024
Q3 		$7.72M Buy
+109,800
New +$9.18M 0.06% 269
2023
Q3 		– Sell
-39,000
Closed -$3.38M – 946
2023
Q2 		$3.38M Buy
+39,000
New +$3.67M 0.04% 291

Other funds holding BMRN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

LMR Partners's BMRN Position: Q1 2026 in Review

LMR Partners increased its BioMarin Pharmaceuticals (BMRN) stake by 1,594% in Q1 2026, buying an estimated $17.8M and bringing the position to 324,939 shares worth $18.4M. The position accounts for 0.04% of the portfolio, ranked #235.

LMR Partners first reported a position in BMRN in Q3 2019 and has held it in 19 quarters since. 554 funds tracked by Wall St. Rank hold BMRN as of Q1 2026.

  • LMR Partners held 324,939 shares of BioMarin Pharmaceuticals worth $18.4M as of Q1 2026.
  • LMR Partners bought 305,761 BioMarin Pharmaceuticals shares in Q1 2026, an estimated $17.8M.
  • BioMarin Pharmaceuticals made up 0.04% of LMR Partners's portfolio in Q1 2026, its #235 holding.
  • LMR Partners first reported a position in BioMarin Pharmaceuticals in Q3 2019 and has held it in 19 quarters since.
  • 554 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.